Richmond Pharmacology

12/07/2023

Interested in working for the UK's leading CRO? Want to do quality research with some of the industry's best? We are recruiting! Take a look at some of the roles available here workatrichmondpharmacology.co.uk/vacancies

10/07/2023

A new competitive prostaglandin-F receptor (FP) antagonist with myometrial selectivity is being developed to reduce uterine contractions during pre-term labour. We carried out the first-in-human study of this therapy, also known as OBE002 to understand its effect on cardiac repolarization.

Take a look at the full study here: assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4e845aa4f64df99cbf473d_OBE022%20(1).pdf

06/07/2023

Accelerating drug development timelines; how do we do it? Watch the video to find out www.youtube.com/watch?v=m0uay9AJ5Gg

04/07/2023

Our database of active Japanese study volunteers has now reached over 20,000!

The database has expanded by 20 times in the last 10 years, and is full of people ready to engage in a study. To find out more information about our patient and volunteer recruitment capabilities, click here www.richmondpharmacology.com/specialist-services/patient-recruitment

02/07/2023

Food ingestion in healthy volunteers leads to an increase in heart rate cardiac stroke volume. When someone consumes a meal, an ECG shows QTc interval shorterning from a fasting baseline up to 7 hours.

Prior observations indicate that calcium block primarily affects early repolarization by shortening the J-T peak c interval. Take a look at our study into the influence of calcium blockade on the QT effects of a meal here: assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4e80367719ad0597722d94_Calcium-blockade-ACCP-Poster-1-WEB.pdf

21/06/2023

What is the secret to our excellent patient and volunteer recruitment track record? Our 22+ years of experience, coupled with our emphasis on the patient and volunteer experience, is paramount to maintaining our extensive database.

Watch the video to find out more or visit richmondpharmacology.com/specialist-services/patient-recruitment

19/06/2023

People with Type 1 Diabetes are often at higher risk of experiencing heart attacks. This disproportionate outcome is concerning, but why does it happen? It could be to do with the effect of high blood sugar on the heart. To understand this occurrence further, we studied the impact of Hyperglycemia on the heart. Read more here assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4e76de19eeb20a2e2b2d53_hERG-blocking-agents-portrait-WEB.pdf

16/06/2023

Today is 2023, and our staff are wearing red to support and raise awareness about clinical research. Our colleagues across the industry working in clinical roles, study participants and regulatory bodies are the powerhouses behind bringing better outcomes to patients.

brings together all parties that support and undertake research. On the front line and behind the scenes, incredible research teams collectively work on health and social care research. For more information, click here https://rdforum.nhs.uk/red4research-2023/

14/06/2023

Many people globally suffer from acid-related disorders such as acid reflux. TAK-438 (or Vanoprazan) is a small molecule, oral potassium-competitive acid blocker that helps suppress gastric acid.

Read more about our study into this drug - which has since received a license to go to market - here: https://ow.ly/MeCw50OLEpm

02/06/2023

Our Associate Training and Education Manager, Lucy Sze says she feels "extremely fortunate to be part of a dynamic and highly motivated team.' Since she joined us three years ago, there have been "many challenging milestones, but the resilience to overcome hardships and come out the other side, provides me with personal/professional leadership experience and motivation to succeed." Read more about Lucy and the rest of our colleagues here workatrichmondpharmacology.co.uk/our-people

Here are some of the people you’ll be working alongside if you join our team.

31/05/2023

It is widely documented in the literature that the consumption of cruciferous vegetables can suppress the initial phase of carcinogenesis or the progression of neoplastic cells to cancer. This may be because of Sulforaphane, a derivative of glucoraphanin. Read more about our Phase 1 study involving a promising non-cytotoxic anti-cancer agent, Sulforadex.

https://assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4eccd2f48d1e1ca0dfe41c_Evgen-BPS-poster-tiny-web.pdf

20/05/2023

We hope you had an enjoyable Clinical Trials Day celebrating this inspiring industry.

Yesterday evening, our colleagues are celebrating their hard work together with a Pizza Party after a productive week bringing new medicines to patients globally.

Let us know how you celebrated in the comments!

20/05/2023

Looking to make the next step in your career in clinical research, but wondering what Richmond Pharmacology has to offer?

Let our current staff tell you! Click the link to hear what our colleagues say about us: [link to landing page]

View our available vacancies here: workatrichmondpharmacology.co.uk/vacancies

20/05/2023

Being able to bring new medicines to market to support a better way of life for people across the globe is at the heart of everything we do.

Today, on Clinical Trials Day, we are taking the time to celebrate the people our services benefit; the patients. Listen to Patrick's story about his struggles with Amyloidosis and how a clinical trial gave him hope that life may become more manageable.

You can watch more volunteer testimonials on our website page at: {website page link}

20/05/2023

On Clinical Trials Day and every day we celebrate our highly skilled team of clinical research professionals who make amazing things happen in modern medicine.

Lucy Sze, Associate Training and Education Manager here at Richmond Pharmacology says: “As a Training & Education Manager in the clinical trials industry, my passion is to empower and equip clinical research professionals with the knowledge, skills, and behaviours required to conduct trials of the highest quality. I believe that investing in the professional development of individuals not only enhances the prospects but also contributes to the overall success of clinical trials and, ultimately, the improvement of patient outcomes.”

To learn more about Richmond Pharmacology and how our team could support you, visit www.richmondpharmacology.com/about

20/05/2023

Today we are celebrating Clinical Trials Day!

The first clinical trial was considered by many to have taken place in 1747 aboard the HMS Salisbury, where scientists tested citrus fruits in the treatment of Scurvy. Today, over 300,000 clinical trials take place every year globally.

Richmond Pharmacology are proud to be part of the industry bringing new treatments to market for the benefit of patients, and to date, we have contributed to over 30 new medicines making it to market www.youtube.com/watch?v=77l5LVcgtwM

To learn more about Clinical Trials Day, visit www.clinicaltrialsday.org

19/05/2023

Meet Laura Onyon, Executive Assistant to our CEO and CMO, Dr Taubel and Dr Lorch.

Laura says that she likes her job because it is so varied; no day is the same. She gets all kinds of interesting requests from across the business, and enjoys working with our highly skilled Executive Board. For more information about working at Richmond Pharmacology, visit workatrichmondpharmacology.co.uk/our-people

Here are some of the people you’ll be working alongside if you join our team.

12/05/2023

Patients and the public experienced rapid availability of new vaccines and treatments against COVID-19 infections during the pandemic in 2020.

The time pressure on clinical researchers and regulators has further increased since then. Join our CEO, Dr Jorg Taubel, and our CMO, Dr Ulrike Lorch, at the Eufemed conference, May 25th-26th and learn more about mastering this new time pressure.

www.richmondpharmacology.com/events/eufemed-conference-mastering-the-new-time-pressure-on-human-pharmacology

10/05/2023

White Blood Cell (WBC) counts are a common subject inclusion criterion for clinical trials as they are indicators of immunocompetence, infection, and inflammation in individuals.

However, some variance can be seen in white blood cell counts, and Richmond Pharmacology has studied the diurnal and racial variance of White Blood Cell Parameters, using Early Phase Clinical Trial data.

Read more about our study here:https://assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4ee3a7309858028a11b0b3_white-blood-cell-WEB.pdf

09/05/2023

Meet Junko, our Occupational Support Manager here at Richmond Pharmacology.

Junko has been with us for 13 years, and has worked across a myriad of projects. Most notably, Junko was involved in developing Japenese audo-assistance and the translation of medical documents, to ensure we are as inclusive as possible.

Learn more about our colleagues via our recruitment website: workatrichmondpharmacology.co.uk/our-people

06/05/2023

We are delighted to celebrate King Charles III and Queen Consort Camilla’s Coronation today alongside the rest of the UK.

The Royal Family have championed important breakthroughs and innovations across the Life Sciences, namely the development of human embryology and fertilisation in the 1980s. King Charles III and Queen Consort Camilla have long been purveyors of health and well-being, and we look forward to their successful reign.

05/05/2023

Interested in hearing more about our services in practice? Visit our case studies page and read about how we apply our operational excellence https://www.richmondpharmacology.com/case-studies

Testimonials left by patients and Case Studies of previous trials.

02/05/2023

Hayfever season is officially upon us, and millions of people across the globe are struggling with troublesome symptoms from pollen.

We conducted a study into the Pharmacokinetics, safety and cognitive effects of Rupatadine, a second generation antihistamine in healthy Japanese volunteers.

Take a look at the full study, including methodology and findings here: http://ow.ly/Rg4850O7K1x

28/04/2023

Hypertension remains the leading cause of death worldwide. Richmond Pharmacology have undertaken several investigations into Hypertension alongside our sponsors.

Watch the video of our CEO, Dr Jorg Taubel presenting the science from one of our studies at a conference recently.

26/04/2023

We are experts in Japanese Bridging Studies. Here at Richmond Pharmacology, we focus mainly on Japanese cohorts in our Bridging Studies in order to fast track global marketing authorisations in these important markets, ultimately reaching patients sooner.

Read the full blog from our Head of Japanese Volunteer Recruitment, Nobuo Ittetsu about how we undertake these studies: www.richmondpharmacology.com/post/bridging-the-gap-in-phase-1-clinical-studies

Different populations and dynamics of people react to drugs in distinct ways. A drug that works for one population may not work for others, and Ethnic Bridging Studies allow pharmaceutical organisations to measure their Investigational Medicinal Product (IMP)’s efficacy on a new population of peop...

25/04/2023

Occult Hepatic Steatosis – How can we distinguish true treatment emerging liver signals from undetected, unrelated liver abnormalities? Read more about our research into Occult Hepatic Steatosis here: assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4ee4288c74e858c565b4b3_occult-hepatic-steatosis-WEB.pdf

21/04/2023

Our Principal Investigators and Co-investigators recently gave expert feedback on the ICH M11 CeSHarP protocol template.

Read more about how we were part of futureproofing the early phase clinical research for the next generation of investigators: www.richmondpharmacology.com/news/futureproofing-early-phase-clinical-research-for-the-next-generation-of-investigators

We are the UK's leading clinical research organisation, successfully conducting over 300 early phase studies since 2001. Speak to our team of experts today.

19/04/2023

Save the date!

Dr Taubel will be attending the Heart Failure Association (HFA)'s annual meeting on from the 20th May - 23rd May in Prague, Czechia. Follow the link for more information: www.richmondpharmacology.com/events/hfa-annual-meeting-2023

19/04/2023

Our Chief Executive Officer, Dr Jorg Taubel and Chief Medical Officer, Dr Ulrike Lorch will be attending the 25th Pharmacokinetics/Pharmacodynamics Expert Meeting from the 20th - 22nd April in Germany!

The two-day meeting will see professionals and experts from around the globe discuss drug interactions, translation sciences, and new approached for drug development in brain diseases.

If you are attending on behalf of your organisation and would like to book a meeting with Dr Taubel and Dr Lorch, please contact us here: www.richmondpharmacology.com/contact

18/04/2023

Premature birth is the leading cause of perinatal mortality and morbidity.

Our study into the effects of OBE022 showed a positive impact, and has since moved through to further stages of study. We are proud to have conducted the First In Human trial for this drug.

Read more here:https://assets.website-files.com/5e4bf3ffdec34954e2ccd80b/5e4ec5be705ea92bc06451a1_oral-prostaglandin-WEB.pdf